Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon

被引:24
|
作者
Scaioli, Eleonora [1 ]
Colecchia, Antonio [1 ]
Marasco, Giovanni [1 ]
Schiumerini, Ramona [1 ]
Festi, Davide [1 ]
机构
[1] Univ Bologna, Policlin S Orsola, Dept Med & Surg Sci, Via Massarenti 9, I-40138 Bologna, Italy
关键词
Diverticular disease; Gut microbiota; Low-grade inflammation; Mesalazine; Probiotics; HIGH-FIBER DIET; DOUBLE-BLIND; MAINTAINING REMISSION; INTERSTITIAL-CELLS; RIFAXIMIN; MESALAZINE; EFFICACY; PROBIOTICS; MECHANISMS; PREVENTION;
D O I
10.1007/s10620-015-3925-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Colonic diverticulosis imposes a significant burden on industrialized societies. The current accepted causes of diverticula formation include low fiber content in the western diet with decreased intestinal content and size of the lumen, leading to the transmission of muscular contraction pressure to the wall of the colon, inducing the formation of diverticula usually at the weakest point of the wall where penetration of the blood vessels occurs. Approximately 20 % of the patients with colonic diverticulosis develop abdominal symptoms (i.e., abdominal pain and discomfort, bloating, constipation, and diarrhea), a condition which is defined as symptomatic uncomplicated diverticular disease (SUDD). The pathogenesis of SUDD symptoms remains uncertain and even less is known about how to adequately manage bowel symptoms. Recently, low-grade inflammation, altered intestinal microbiota, visceral hypersensitivity, and abnormal colonic motility have been identified as factors leading to symptom development, thus changing and improving the therapeutic approach. In this review, a comprehensive search of the literature regarding on SUDD pathogenetic hypotheses and pharmacological strategies was carried out. The pathogenesis of SUDD, although not completely clarified, seems to be related to an interaction between colonic microbiota alterations, and immune, enteric nerve, and muscular system dysfunction (Cuomo et al. in United Eur Gastroenterol J 2:413-442, 2014). Greater understanding of the inflammatory pathways and gut microbiota composition in subjects affected by SUDD has increased therapeutic options, including the use of gut-directed antibiotics, mesalazine, and probiotics (Bianchi et al. in Aliment Pharmacol Ther 33:902-910, 2011; Comparato et al. in Dig Dis Sci 52:2934-2941, 2007; Tursi et al. in Aliment Pharmacol Ther 38:741-751, 2013); however, more research is necessary to validate the safety, effectiveness, and cost-effectiveness of these interventions.
引用
收藏
页码:673 / 683
页数:11
相关论文
共 50 条
  • [31] Diverticular disease: A therapeutic overview
    Antonio Tursi
    World Journal of Gastrointestinal Pharmacology and Therapeutics, 2010, 1 (01) : 27 - 35
  • [32] Efficacy of Mesalazine in the Treatment of Symptomatic Diverticular Disease
    Francesco Di Mario
    Giovanni Aragona
    Gioacchino Leandro
    Giuseppe Comparato
    Libera Fanigliulo
    Lucas G. Cavallaro
    Giulia M. Cavestro
    Veronica Iori
    Marta Maino
    AlÌ M. Moussa
    Alessandro Gnocchi
    Giancarlo Mazzocchi
    Angelo Franzé
    Digestive Diseases and Sciences, 2005, 50 : 581 - 586
  • [33] Efficacy of mesalazine in the treatment of symptomatic diverticular disease
    Di Mario, F
    Aragona, G
    Leandro, G
    Comparato, G
    Fanigliulo, L
    Cavallaro, LG
    Cavestro, GM
    Iori, V
    Maino, M
    Moussa, AM
    Gnocchi, A
    Mazzocchi, G
    Franzé, A
    DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (03) : 581 - 586
  • [34] Symptomatic Uncomplicated Diverticular Disease (SUDD): Practical Guidance and Challenges for Clinical Management
    Calini, Giacomo
    Aziz, Mohamed A. Abd El
    Paolini, Lucia
    Abdalla, Solafah
    Rottoli, Matteo
    Mari, Giulio
    Larson, David W.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2023, 16 : 29 - 43
  • [35] New physiopathological and therapeutic approaches to diverticular disease: an update
    Tursi, Antonio
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (07) : 1005 - 1017
  • [36] Pathophysiology of diverticular disease
    Schieffer, Kathleen M.
    Kline, Bryan P.
    Yochum, Gregory S.
    Koltun, Walter A.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 12 (07) : 683 - 692
  • [37] Diverticular disease: a new therapeutic opportunity
    Aragona, S. E.
    Pasquale, L.
    Fedeli, P.
    Galloro, G.
    Carrara, P. Da Massa
    Iannuzziello, D.
    Paiano, P.
    Savarino, E.
    Vinti, M.
    Ciprandi, G.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2022, 36 (02) : 59 - 64
  • [38] Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon
    Tursi, A.
    Papa, A.
    Danese, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (06) : 664 - 684
  • [39] High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease
    Edith Lahner
    Gianluca Esposito
    Angelo Zullo
    Cesare Hassan
    Claudio Cannaviello
    Maria Carla Di Paolo
    Lorella Pallotta
    Nicoletta Garbagna
    Enzo Grossi
    Bruno Annibale
    World Journal of Gastroenterology, 2012, (41) : 5918 - 5924
  • [40] Absence of Mucosal Inflammation in Uncomplicated Diverticular Disease
    Elli, Luca
    Roncoroni, Leda
    Bardella, Maria Teresa
    Terrani, Claudia
    Bonura, Antonella
    Ciulla, Michele
    Marconi, Stefano
    Piodi, Luca
    DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (07) : 2098 - 2103